De Jong et al. found that the presence of many CD8+ TILs was an independent predictor of enhanced OS (total cohort and type II), and that a high CD8+/FoxP3+ ratio [25,26] was an independent predictor of increased disease-free survival (DFS) in type I, but not type II, endometrial cancer patients. The gene discussed is CD8A; the disease is endometrial cancer.